Subtle Medical, an AI-powered medical imaging company, has been awarded funding from the second phase of an NIH Small Business Innovation Research (SBIR) grant to expand its SubtleSYNTH technology into brain imaging.
The company FDA approved In spinal cord imaging, synthetic short tau inversion recovery (STIR) images (SynthSTIR) are generated from previously acquired T1- and T2-weighted contrast.
The company says the approval marks a major advancement in MRI technology, reducing SynthSTIR acquisition times to zero while maintaining clinical quality comparable to traditional STIR images.
SubtleSYNTH is the latest addition to the company’s AI-driven product suite, which also includes SubtleMR and SubtlePET software.
SubtleSYNTH aims to improve the efficiency and accuracy of MRI scans, benefiting both patients and imaging companies by addressing exam delays, long wait times and scheduling challenges, the company said in a statement.
“We are excited to receive Phase II funding to expand our SubtleSYNTH technology,” Ajit Shankaranarayanan, chief product officer at Subtle Medical, said in a statement.
“This grant not only demonstrates the scientific value of our approach, but also empowers us to push the boundaries of what’s possible in medical imaging. With FDA clearance for spine imaging and support from the NIH, we’re poised to bring this innovative technology to brain imaging, further improving the speed, quality and safety of MRI exams.”
Larger trends
July 24th, Delicate medical treatment The company raised nearly $10 million in its Series B+ round, bringing its Series B funding to over $30 million and its total funding to over $50 million.
The funding was used to accelerate sales efforts in the U.S. and around the world and to accelerate the launch of new AI-powered products.
SubtleSYNTH is the company’s FDA Approved SubtleMR software speeds up image acquisition for MRI procedures by up to 60% across all vendors’ products.
The HIMSS Healthcare Cybersecurity Forum is scheduled to take place October 31-November 1 in Washington, DC.
